GlaxoSmithKline and Access to Essential Medicines (B)

Journal of Business Ethics Education 2 (1):123-132 (2005)
  Copy   BIBTEX

Abstract

The (B) case summarizes GSK’s response to pressures to increase access to essential medicines in developing countries and subsequent developments.

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 93,990

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

Similar books and articles

GlaxoSmithKline and Access to Essential Medicines (B).N. Craig Smith & Anne Duncan - 2005 - Journal of Business Ethics Education 2 (1):123-132.
Patent Funded Access to Medicines.Tom Andreassen - 2014 - Developing World Bioethics 15 (3):152-161.
Poverty, Disease, and Medicines in Low- and Middle-Income Countries.Klaus M. Leisinger - 2012 - Business and Professional Ethics Journal 31 (1):135-185.

Analytics

Added to PP
2012-03-18

Downloads
29 (#538,959)

6 months
11 (#339,290)

Historical graph of downloads
How can I increase my downloads?

Citations of this work

Moral Luck and Business Ethics.Christopher Michaelson - 2008 - Journal of Business Ethics 83 (4):773-787.
BB&T, Atlas Shrugged.S. Douglas Beets - 2015 - Journal of Academic Ethics 13 (4):311-344.

Add more citations

References found in this work

No references found.

Add more references